Chemotherapy for the Brain: The Antitumor Antibiotic Mithramycin Prolongs Survival in a Mouse Model of Huntington’s Disease

Robert J. Ferrante,1 Hoon Ryu,1 James K. Kubilus,1 Santosh D’Mello,2 Katharine L. Sugars,3 Junghoo Lee,4 Peiyuan Lu,4 Karen Smith,5 Susan Browne,6 M. Flint Beal,7 Bruce S. Kristal,7,8 Irina G. Stavrovskaya,7,8 Sandra Hewett,9 David C. Rubinsztein,3 Brett Langley,4 and Rajiv R. Ratan4,5,6,7,8

1Geriatric Research and Education and Clinical Center, Veterans Administration Medical Center, Bedford, Department of Neurology, Pathology, and Psychiatry, Boston University School of Medicine, Boston, Massachusetts 02118, 2Department of Molecular and Cellular Biology, University of Texas at Dallas, Richardson, Texas 75083, 3Department of Medical Genetics, Cambridge Institute for Medical Research, Cambridge, CB2 2XY United Kingdom, 4Department of Neurology, 5Program in Neuroscience, and 6Center for Neurodegeneration and Repair, Harvard Medical School and The Beth Israel Deaconess Medical Center, Boston, Massachusetts 02115, 7Department of Neurology and Neuroscience, Weil Medical College of Cornell University, New York, New York 10021, 8Burke Medical Research Institute, White Plains, New York 10605, and 9University of Connecticut School of Medicine, Farmington, Connecticut 06030

Introduction

Huntington’s disease (HD) is a fully penetrant autosomal-dominant inherited neurological disorder caused by expanded CAG repeats in the Huntingtin gene. Transcriptional dysfunction, excitotoxicity, and oxidative stress have all been proposed to play important roles in the pathogenesis of HD. This study was designed to explore the therapeutic potential of mithramycin, a clinically approved guanosine–cytosine-rich DNA binding antitumor antibiotic. Pharmacological treatment of a transgenic mouse model of HD (R6/2) with mithramycin extended survival by 29.1%, greater than any single agent reported to date. Increased survival was accompanied by improved motor performance and markedly delayed neuropathological sequelae. To identify the functional mechanism for the salubrious effects of mithramycin, we examined transcriptional dysfunction in R6/2 mice. Consistent with transcriptional repression playing a role in the pathogenesis of HD, we found increased methylation of lysine 9 in histone H3, a well established mechanism of gene silencing. Mithramycin treatment prevented the increase in H3 methylation observed in R6/2 mice, suggesting that the enhanced survival and neuroprotection might be attributable to the alleviation of repressed gene expression vital to neuronal function and survival. Because it is Food and Drug Administration-approved, mithramycin is a promising drug for the treatment of HD.

Key words: mithramycin; Huntington’s disease; HD; Huntingtin; Htt; histone methylation; neuroprotection; transcription

Huntington’s disease (HD) is a fully penetrant autosomal-dominant inherited neurological disorder caused by expanded CAG repeats in the Huntingtin gene. Transcriptional dysfunction, excitotoxicity, and oxidative stress have all been proposed to play important roles in the pathogenesis of HD. This study was designed to explore the therapeutic potential of mithramycin, a clinically approved guanosine–cytosine-rich DNA binding antitumor antibiotic. Pharmacological treatment of a transgenic mouse model of HD (R6/2) with mithramycin extended survival by 29.1%, greater than any single agent reported to date. Increased survival was accompanied by improved motor performance and markedly delayed neuropathological sequelae. To identify the functional mechanism for the salubrious effects of mithramycin, we examined transcriptional dysfunction in R6/2 mice. Consistent with transcriptional repression playing a role in the pathogenesis of HD, we found increased methylation of lysine 9 in histone H3, a well established mechanism of gene silencing. Mithramycin treatment prevented the increase in H3 methylation observed in R6/2 mice, suggesting that the enhanced survival and neuroprotection might be attributable to the alleviation of repressed gene expression vital to neuronal function and survival. Because it is Food and Drug Administration-approved, mithramycin is a promising drug for the treatment of HD.

Key words: mithramycin; Huntington’s disease; HD; Huntingtin; Htt; histone methylation; neuroprotection; transcription
these impressive advances, clinically approved agents that modulate transcription in a manner that would be favorable for HD patients have yet to be identified.

Mithramycin, an aureolic acid-type polyketide produced by the soil bacteria *Streptomyces agrillaceus*, is a clinically approved antibiotic used for the treatment of hypercalcemia and several types of cancers (Jones et al., 1995). Mithramycin binds to DNA sequences with guanosine–cytosine (GC) base specificity and has been shown to interfere with DNA binding proteins, such as Sp1 family transcription factors, which bind to GC-rich DNA sequences. In this regard, mithramycin has been shown to inhibit the expression of some proto-oncogenes, such as c-myc, and have an important role in the regulation of cell proliferation and differentiation (Jones et al., 1995). With regard to neuroprotection, previous studies from this laboratory have demonstrated that mithramycin can inhibit glutathione-depletion oxidative stress-induced death of cultured primary cortical neurons in culture (Chatterjee et al., 2001). These studies correlated the protective effects of mithramycin with its ability to bind to GC-rich DNA and displace Sp1 family transcription factors (Chatterjee et al., 2001).

Herein, we show that mithramycin prolongs survival, improves functional motor performance, and markedly improves brain neuropathological sequelae in the R6/2 transgenic mouse HD model. Furthermore, we show that methylation of lysine 9 in histone H3, a well-established mechanism of gene silencing and transcriptional repression, is increased in R6/2 mice. Congruent with its protective effects, we show that mithramycin treatment prevents this histone H3 hypermethylation in the R6/2 line.

Materials and Methods

**Animals.** Male transgenic HD mice (R6/2 strain) were obtained from The Jackson Laboratory (Bar Harbor, ME) and maintained as a colony at the Bedford Veterans Medical Center. The male R6/2 mice were bred with females from their background strain (B6CBAF1/J), and offspring were genotyped using PCR. The mice were housed (five per cage) under standard conditions with access to water and food *ad libitum*. To ensure homogeneity of experimental cohorts, criteria for placement of mice into testing groups were standardized. Age-matched (within 4 d) mice from 31 litters of the same “F” generation were randomized. Any mice that had altered base-paired banding identified from PCR analysis were excluded from the study. All mice were weighed at 20 d of age and equally distributed according to weight within each cohort. Mice under 7 gpm were not used in the experiments. Enrichment conditions were not applied to cages because of its effect on improving phenotype in R6/2 mice. All mice were handled under the same conditions by one investigator. All animal experiments were performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved by both the Veterans Administration and Boston University Animal Care Committees.

**Intraperitoneal dosing.** Based on the study of Chatterjee et al. (2001), we completed a dose–response study, treating wild-type and R6/2 mice with 50, 100, 150, 300, and 600 μg/kg daily intraperitoneal injection of mithramycin A (Serva Feinbiochemica, Heidelberg, Germany) dissolved in PBS. Control groups were treated with PBS injection or untreated. Behavioral and survival data were obtained from −120 R6/2 and 120 littermate wild-type mice. During the temporal progress of the disease, the intraperitoneal injection was 100 μl per mouse until death.

**Body weight.** Body weights were recorded twice weekly at the same time of day in all groups.

**Motor performance.** Motor performance was assessed weekly from 21–63 d of age and twice weekly from 63 d of age in the mithramycin-treated (150 μg/kg) and untreated R6/2 mice. The mice were given two training sessions to acclimate them to the rotorod apparatus (Columbus Instruments, Columbus, OH). Mice were placed on a rotating rod at 16 rpm. The length of time on the rod was taken as the measure of compe-

**Survival.** R6/2 mice were observed twice daily, mid-morning and late afternoon. Their motor performance and ability to feed was closely monitored and was the basis for determining when to kill the mice. The criteria for being killed was the point in time in which the HD mice were unable to right themselves after being placed on their back and initiate movement after being gently prodded for 30 sec. Two independent observers confirmed the criteria for being killed (R.J.F. and J.K.K.).

**3-Nitropionic acid administration.** At 42 d, groups of 10 R6/2 mice were treated daily with 150 μg/kg mithramycin intraperitoneally or PBS for 2 weeks. At the beginning of the second week, 3-nitropionic acid (3-NP) (Sigma, St. Louis, MO), freshly dissolved in PBS (pH adjusted to 7.4), was injected intraperitoneally nine times at 12 hr intervals (75 mg/kg) in R6/2 mice. Mice were deeply anesthetized 8–10 hr after the last 3-NP injection, transcardially perfused with buffered 4% paraformaldehyde, and then processed for histopathologic evaluation. These experiments were repeated twice, using cohorts of eight mice in the subsequent groups for a total of 52 mice. Glycerol cryoprotected brains were frozen sectioned at 50 μm and stained with cresyl violet for general cell staining. Quantitative analysis of lesion volumes was performed in serial sections as described below.

**Histological evaluation.** At 21 d, R6/2 transgenic mice and wild-type littermate control mice were treated with daily 150 μg·kg⁻¹·52 d⁻¹ intraperitoneal mithramycin or PBS. At 90 d of age, groups of 10 animals from each treatment paradigm were deeply anesthetized and transcardially perfused with 4% buffered paraformaldehyde. Approximately 40 mice were used for data collection in the neuropathological analysis and processed for histopathology, as described previously (Ferrante et al., 2003). Serially cut tissue sections were stained for Nissl substance and immunostained for htt, using a polyclonal rabbit antibody (EM48; dilution, 1:1000; Chemicon, Temecula, CA), and ubiquitin (rabbit polyclonal; dilution, 1:500; Dako, High Wycombe, UK), using a previously reported conjugated secondary antibody method in murine brain tissue samples (Ferrante et al., 2003). Specificity for the antisera used in this study was examined in each immunological experiment to assist with interpretation of the results. Preabsorption with excess target proteins, omission of the primary antibodies, and omission of secondary antibodies was performed to determine the amount of background generated from the detection assay.

**Immunoblot analysis.** For Western blotting, brain tissue was homogenized in 2.5 × volume 50 mM Tris-HCl, 10% glycerol, 5 mM magnesium acetate, 0.2 mM EDTA, and 0.5 mM DTT, and protein concentration was determined using the DC protein assay kit (Bio-Rad, Hercules, CA). Ten micrograms of each sample were subjected to SDS-PAGE (10%) as described previously in a clonal; dilution, 1:500; Dako, High Wycombe, UK), using a previously reported conjugated secondary antibody method in murine brain tissue samples (Ferrante et al., 2003). Specificity for the antisera used in this study was examined in each immunological experiment to assist with interpretation of the results. Preabsorption with excess target proteins, omission of the primary antibodies, and omission of secondary antibodies was performed to determine the amount of background generated from the detection assay.

**Promoter activity analysis for Htt transgene expression.** Htt-promoter analysis was performed using a promoter-reporter construct containing −1032 to −15 of the 5′ regulatory region of the human htt gene as described previously (Coles et al., 1998). The SK-N-SH neuroblastoma cell line was used in the transient transfection assays and was treated with mithramycin at 100 or 200 nM for the indicated times. Reporter activity assays, at 48 hr after transfection, and data analysis were performed as described previously (Coles et al., 1998).

**Stereology—quantitation.** Serial-cut coronal tissue sections from the rostral segment of the neostriatum at the level of the anterior commissure (interaural 5.34 mm, bregma 1.54 mm to interaural 3.7 mm, bregma −0.10 mm) were used for htt aggregate analysis. Unbiased stereological counts of htt-positive aggregates (>1.0 μm) were obtained from the neostriatum in 10 mice each from mithramycin-treated and PBS-treated R6/2 mice at 90 d using Neurolucida Stereo Investigator software (MicroBrightField, Colchester, VT). The total areas of the neostriatum were defined in serial sections in which counting frames were randomly sampled. The optical dissector counting method was used in which htt-
positive aggregates were counted in an unbiased selection of serial sections in a defined volume of the neostriatum. Striatal neuron areas were analyzed by microscopic video capture using a Windows-based image analysis system for area measurement (Optimas Bioscan, Edmonds, WA). The software automatically identifies and measures profiles. All computer-identified cell profiles were manually verified as neurons and by differential centrifugation protocols essentially as described previously (Kristal and Brown, 1999), with the following modifications. After decapitation, livers were rapidly dissected out and placed in ice-cold 300 mM sucrose, 10 mM HEPES, and 1 mM EGTA, pH 7.4 with KOH and supplemented with 0.5% fatty acid-free bovine serum albumin (BSA) (A-6003; Sigma). Livers were homogenized with a motor-driven Teflon pestle. After homogenization, samples were centrifuged at 1000 × g for 10 min. Supernatants were removed and centrifuged at 8000 × g for 10 min. Pellets were washed twice before final resuspension. The first wash was in homogenization buffer; the final wash and resuspension buffer had no EGTA or BSA. Mitochondrial permeability transition (MPT) induction was monitored spectrophotometrically as described previously (Kristal and Brown, 1999). Changes in absorbance at 560 nm (A560) were followed for 1 hr using a SpectraMax Plate Reader (Molecular Dynamics, Sunnyvale, CA).

Statistics. The data are expressed as the mean ± SEM. Statistical comparisons of rotarod, weight data, and histology data were compared by ANOVA or repeated-measures ANOVA. Survival data were analyzed by the Kaplan–Meier survival curves.

Results

Mithramycin extends survival, enhances motor performance, and improves brain histopathology in R6/2 mice

Because the R6/2 transgenic mice, which express exon 1 of the human expanded CAG repeat-containing Huntingtin gene, display similar clinical and pathological features to those found in humans who have HD; they represent a reasonable model with which to identify candidate therapies for testing in humans. Mithramycin improved survival in a dose-dependent manner (Fig. 1A). The optimal mithramycin dose (150 μg·kg⁻¹·d⁻¹, i.p.) extended survival in R6/2 mice by 29.1% (p < 0.001), greater than any other single neuroprotective agent reported to date (Fig. 1A). Doses at 300 and 600 μg·kg⁻¹·d⁻¹ resulted in morbidity and death, respectively. Mithramycin (150 μg·kg⁻¹·d⁻¹) also significantly improved rotarod performance, a complex locomotor test, at all times tested (4–17 weeks) during the lifespan of the R6/2 mice compared with vehicle-treated R6/2 mice (Fig. 1B). The combined improvement in rotarod performance was 42.6%. The weight curves of mithramycin-treated and vehicle-treated R6/2 mice closely paralleled one another, maintaining a plateau at 19–20 gm until death ensued within each treatment group. Significant differences in body weight occurred as an epiphenomenon of survival extension and not as a primary independent event related to mithramycin treatment.

A marked improvement in neuropathological sequelae was also observed in R6/2 mice treated with mithramycin. Mithramycin (150 μg·kg⁻¹·d⁻¹) prevented brain atrophy, ventricular hypertrophy, and striatal neuronal atrophy seen in R6/2 mice (Fig. 1D–I). Indeed, gross brain atrophy with bilateral ventricular hypertrophy and flattening of the medial aspect of the stratum, present in the brains of R6/2 mice at 90 d of age, are essentially absent from R6/2 mice treated with mithramycin (Fig. 1E,F). There was a 21.3% reduction in brain weight in vehicle-
treated R6/2 mice compared with littermate wild-type mice. In contrast, there was only a 2.8% brain weight loss in R6/2 mice treated with mithramycin (wild-type littermate mice, 456 ± 11 mg/kg; PBS-treated R6/2 mice, 359 ± 21 mg/kg, p < 0.001; 150 μg · kg⁻¹ · d⁻¹ mithramycin-treated R6/2 mice, 443 ± 16 mg/kg, p < 0.12). Similarly, there was no significant difference in neuronal size between mithramycin-treated R6/2 mice and littermate wild-type mice at 90 d (mithramycin-treated R6/2 mice, 127.3 ± 14.0 μm²; wild-type littermate control mice, 131.4 ± 12.7 μm²). In contrast to this, vehicle-treated R6/2 mice displayed a 41.9% decrease in neuronal size (55.1 ± 21.2 μm², p < 0.001). These results clearly demonstrate that mithramycin is neuroprotective, enhances functional status, and improves survival in R6/2 mice.

Mithramycin has been shown to interact with the minor groove of DNA with a GC base specificity (Jones et al., 1995). To examine whether alternate DNA binding drugs had a similar neuroprotective effect to mithramycin, R6/2 mice were treated with distamycin. Distamycin, a drug that binds the minor groove with adenosine–thymidine (AT) base specificity, had no effect on survival or rotarod performance in the R6/2 mice (Fig. 1C), suggesting that not all DNA binding drugs are protective in the R6/2 model. In fact, this lack of effect suggests that GC base specificity may be a necessary component of the neuroprotective effects of mithramycin.

**Mithramycin does not interfere with mutant htt transgene expression**

The human htt promoter drives expression of the mutant htt transgene in the R6/2 model (Coles et al., 1998). This promoter has been found to have several essential GC-rich DNA binding sites that are legitimate binding sites for transcription factors such as Sp1 or BTEB (basic transcription element binding) (Coles et al., 1998). The established ability of mithramycin to displace transcriptional activators that bind to GC-rich binding sites (Jones et al., 1995) raised the possibility that mithramycin prevents neuronal dysfunction in the R6/2 model by decreasing expression of the toxic transgene. To evaluate this possibility, we examined the level of mutant htt exon 1 transgene expression in mithramycin-treated R6/2 mice compared with their vehicle-treated controls. The mean relative htt protein expression for treated versus untreated mice was 0.934 ± 0.171 (p = 0.028) (Fig. 2A), suggesting that mithramycin does not alter htt transgene expression in these mice. To examine the matter further, human SK-N-SH cells were treated with a supratherapeutic concentration of mithramycin (100 nM/l), and mutant htt mRNA levels and htt promoter activity were examined. The results demonstrated that mithramycin did not influence either mutant htt mRNA levels or htt promoter activity in vitro (data not shown). To further demonstrate that protection was not a result of decreased htt expression, htt-positive or ubiquitin-positive striatal aggregates were examined in mithramycin-treated R6/2 mice at 90 d of age. Mithramycin treatment had no significant effect on either htt-positive or ubiquitin-positive striatal aggregates (Fig. 2B).

The treatment of mice with 3-NP, an irreversible inhibitor of succinate dehydrogenase that inhibits both the Krebs’ cycle and complex II of the mitochondrial electron transport chain, produces selective striatal lesions that replicate some of the characteristic histopathological features of HD (Beal et al., 1993; Brouillet et al., 1995). Thus, 3-NP treatment presents an appropriate htt transgene-independent model by which to examine the protective effects of mithramycin. As expected, the administration of 3-nitropropionic acid in mice resulted in striatal toxicity and the development of striatal lesions (Fig. 3). In contrast, 3-NP-treated mice, which were treated with mithramycin, displayed lesion volumes that were markedly reduced or not present at all (mithramycin treated 3-NP R6/2 mice, 0.87 ± 0.41 mm³; PBS-treated 3-NP R6/2 mice, 10.6 ± 3.09 mm³; p < 0.001). There was a 91% reduction in lesion volume in the mithramycin-treated R6/2 mice (Fig. 3). Together, these findings demonstrate that mithramycin does not exert its salutary effects by reducing mutant Huntington transgene expression in mice. Rather, they argue that mithramycin acts downstream of mutant htt expression to stem neuronal injury and disease progression.

**Mithramycin does not protect by altering glutamate receptor expression or activity**

Because excitotoxicity is believed to be a contributor to neuronal dysfunction in Huntington’s disease (Ferrante et al., 2002), it is possible that mithramycin enhances motor function and attenuates neuronal dysfunction by directly affecting the expression or activity of glutamate receptors. We therefore examined the effect of mithramycin on excitotoxic cell death in vitro. Cortical neurons, a cell type afflicted in HD, were treated with NMDA alone or in the presence of mithramycin. Mithramycin failed to protect cells from this NMDA-induced injury (Table 1). This lack of effect could not be attributed to loss of drug activity because
Mithramycin does not modulate mitochondrial permeability transition induction threshold

Impaired mitochondrial function has also been implicated as an important contributor to HD pathogenesis. Mitochondria, isolated from lymphoblasts of HD patients and transgenic mice, have been shown to have an increased susceptibility to depolarize in response to proapoptotic stress (Sawa et al., 1999) and gradual calcium loads (Panov et al., 2002) compared with mitochondria from controls. Furthermore, mutant htt has been demonstrated to induce MPT pore opening in isolated mouse liver mitochondria (Fig. 5, trace A). In contrast to cyclosporine A, coincubation of mitochondria with the MPT inhibitor cyclosporine A (250 nm) reduced mitochondrial swelling (Fig. 5, trace A). A concentration-dependent manner (Chatterjee et al., 2001). The ability of mithramycin to prevent death during activity deprivation and growth factor deprivation in pure cerebellar granule neuron cultures (D’Mello et al., 1993) was examined. In this, another glutamate receptor-independent cell death model, mithramycin blocked neuronal death induced by both activity and growth factor deprivation (Fig. 4). Together, these results suggest that the salubrious effects of mithramycin are independent of glutamate receptors.

The levels seen in wild-type controls, suggesting that mithramycin treatment prevented the htt-induced H3 methylation increase (Fig. 6). Together, these findings are consistent with increased transcriptional dysfunction playing a neuropathogenic role in the R6/2 HD model and suggest that mithramycin improves this neuropathogenic outcome by partially restoring perturbed gene transcription.

Discussion

This study found that mithramycin treatment, given intraperitoneally at 150 μg · kg⁻¹ · 52 d⁻¹, was well tolerated and improved many of the Huntington’s disease-associated symptoms in R6/2 transgenic mice. Specifically, mithramycin prolonged survival and improved functional motor performance. Furthermore, whereas the brains of untreated R6/2 mice displayed brain atrophy, ventricular hypertrophy, and striatal neuronal atrophy, histological sections from mithramycin-treated R6/2 mice and their wild-type littermates were virtually indistinguishable at 90 d of age. In agreement with these findings, mithramycin also markedly reduced lesion volumes in 3-NP-treated mice, another model of Huntington’s disease. Mithramycin treatment prevented striatal damage in R6/2 mice (top) compared with PBS-treated R6/2 mice (bottom). Scale bar, 2 mm.

Figure 3. Mithramycin neuroprotection from 3-nitropropionic acid toxicity in R6/2 mice. Mithramycin treatment prevented striatal damage in R6/2 mice (top) compared with PBS-treated R6/2 mice (bottom). Histopathological evaluation of 3-NP-induced striatal lesions shows bilateral striatal lesions, areas of pallor, in PBS-treated R6/2 mice (bottom). Scale bar, 2 mm.
model in which HD-like striatal lesions are induced (Beal et al., 1993; Brouillet et al., 1995).

Previous studies in mice have shown that intraperitoneal administration of a single dose of 150 μg/kg is sufficient to inhibit expression of a c-myc promoter reporter construct in the brain by 90% (Jones et al., 1995). These findings suggest that mithramycin penetrates the blood–brain barrier to exert some of its beneficial effects. Furthermore, these protective effects appear to require GC DNA specificity, because an AT DNA binding antibiotic, dextramycin, had no effect on either R6/2 transgenic mouse survival or rotorod performance. It is less clear, however, whether or not these protective effects are mediated through displacing the Sp1 family of transcriptional activators from their canonical GC DNA binding sites. It is plausible that Sp1 could transcriptionally activate a hitherto unknown gene or number of genes that are involved in promoting neuronal death. Alternatively, Sp1 could be acting directly or indirectly to repress transcription of a prosurvival gene(s). In either scenario, inhibiting Sp1 from binding DNA would result in reduced or delayed neuronal dysfunction and death. Investigations are currently underway to determine whether Sp1 displacement is critical for mediating the protective effects of mithramycin. However, based on reports demonstrat-
Because the etiology of HD pathogenesis has been linked to mechanisms of global transcriptional repression such as epigenetic histone modification, we focused on htt- and mithramycin-induced changes in histone acetylation and methylation. Consistent with repressed transcriptional activity in HD, we detected increased histone H3 lysine 9 methylation in R6/2 transgenic mice. This increased H3 methylation was prevented by mithramycin treatment. Posttranslational modifications of histone tails, including acetylation, phosphorylation, and methylation, play important roles in regulating transcription and chromatin structure. Methylation of histone H3 has been linked to distinct effects on transcription, depending on the enzyme and residue modified. That mithramycin prevented htt-induced hypermethylation is compatible with a model in which mithramycin could displace the GC-rich DNA binding of a histone methyltransferase (HMT) or a transcription factor that recruits an HMT and reduce associated gene silencing. Indeed, evidence that DNA binding transcription factors can recruit an HMT to specific gene promoters to repress transcription is established. For example, the histone H3-specific methyltransferase, G9a, responsible for H3 lysine 9 methylation and demethylation within silent euchromatin (Rice et al., 2003), has been shown recently to interact with CCAAT displacement protein/cut homolog (C/EBP) proteins (Nishio and Walsh, 2004), which have been characterized to function as transcriptional repressors in a large number of genes, including p21(waf1/cip1), gp91phox, c-myc, and histones (Skalnik et al., 1991; Dufort and Nepveu, 1994; el-Hodiri and Perry, 1995; Coqueret et al., 1998; Li et al., 1999). Consistent with its role as a transcriptional repressor, C/EBP/cut was demonstrated to recruit G9a to the human p21(waf1/cip1) promoter, in which H3 lysine 9 methylation and transcriptional repression occurs (Nishio and Walsh, 2004). Although no HMT-interacting GC-rich DNA binding proteins have been reported to date, the idea that mithramycin could displace such a factor is an appealing one. The ensuing enhanced gene expression at such sites may counteract the toxicity of the HD mutation either directly by opposing the hyperactive corepressor function of htt and/or by mediating a more generic protective response. This is analogous to what may occur with histone deacetylase inhibitors that protect against both polyglutamine-dependent and-independent insults (Ferrante et al., 2003; Ryu et al., 2003b).

The identification of the gene for HD has facilitated the development of rodent models to screen for novel therapeutics. These screens have elucidated a host of agents. Additional agents are needed, however, to complement or surpass the antioxidant and anti-glutamate strategies currently under investigation in humans with HD. Human clinical trials are expensive, and even the largest trials have only a limited power to detect a beneficial effect. The comparatively large effect of mithramycin, an Food and Drug Administration-approved drug, argues that it should be among the top priorities for testing in patients.

References


